Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Director Paolo Fundaro sold 2,171 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, March 29th. The stock was sold at an average price of $107.45, for a total value of $233,273.95. Following the transaction, the director now owns 11,114 shares of the company’s stock, valued at $1,194,199.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of ICPT opened at $87.38 on Friday. Intercept Pharmaceuticals Inc has a 12-month low of $64.50 and a 12-month high of $133.74. The company has a debt-to-equity ratio of 19.41, a current ratio of 4.22 and a quick ratio of 4.22.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) EPS for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The company had revenue of $53.30 million during the quarter, compared to the consensus estimate of $52.53 million. During the same quarter last year, the firm posted ($4.43) EPS. The company’s quarterly revenue was up 41.4% on a year-over-year basis. Analysts anticipate that Intercept Pharmaceuticals Inc will post -9.13 EPS for the current fiscal year.
Several analysts recently issued reports on ICPT shares. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research note on Monday, December 31st. Raymond James restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 14th. Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $99.00 to $130.00 in a research note on Monday, January 14th. Jefferies Financial Group lifted their price objective on Intercept Pharmaceuticals to $150.00 and gave the company a “buy” rating in a report on Monday, January 28th. Finally, Needham & Company LLC raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Thursday, January 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $144.05.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: Current Ratio
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.